Broncus Holding Corporation (HKG:2216) has successfully completed the first case of registered clinical trials for its targeted lung denervation radiofrequency ablation system. The trial, led by Professor Luo Fengming at the West China Hospital of Sichuan University, is a multi-center study aimed at evaluating the safety and effectiveness of Broncus' denervation ablation system in treating Chron..
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2..
Experts suggest that expanding eligibility for amyotrophic lateral sclerosis (ALS) trials could benefit patients and drug development. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which is an understatement according to investigators. Expanding inclusion criteria would allow more patients to access experimental treatments and help drug develope..
Expanding eligibility criteria for early-phase ALS clinical trials could benefit both patients and therapeutic progress, according to experts. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which has ethical and drug development implications. Angela Genge, chief medical officer at QurAlis, believes that expanding eligibility is necessary to allow..
The Bespoke Gene Therapy Consortium, managed by the Foundation for the National Institutes of Health (NIH), has selected eight rare diseases for its clinical trials program. The consortium aims to accelerate gene therapy development targeting rare diseases with few therapeutic options. The BGTC will develop protocols for first-in-human trials for Charcot-Marie-Tooth disease type 4J, congenital h..
The global stem cell therapy market is projected to reach USD 31.41 billion by 2030, growing at a CAGR of 13.73% during the forecast period from 2023 to 2030. The market size was estimated at USD 11.22 billion in 2022 and is expected to expand to USD 24.29 billion by 2028. Factors driving the growth of the market include accelerated funding for stem cell therapies, rising interest in stem cell-b..
Japanese pharmaceutical company Astellas Pharma has partnered with Kate Therapeutics to develop a gene therapy for X-linked myotubular myopathy (XLMTM), a rare and life-threatening neuromuscular disease leading to severe muscle weakness. The partnership aims to reduce the likelihood of severe side effects by using significantly lower doses of viral vectors responsible for delivering genes into p..
